Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 3Hodgkin Disease 3Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Neoplasms by Site 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia 1Carcinoma, Renal Cell 1Bronchiolitis Obliterans Syndrome 1

Interventions

tofacitinib 7ibrutinib 6ruxolitinib 3ofatumumab 3asciminib 3Imatinib Mesylate 3Dasatinib 3nilotinib 2bosutinib 2Rituximab 2Oxycodone 2Naloxone 2KW-2478 2sodium luminolate 1oblimersen 1obinutuzumab 1mocetinostat 1milatuzumab 1ixekizumab 1fenebrutinib 1canakinumab 1belumosudil 1baricitinib 1axatilimab 1abexinostat 1Vision, Ocular 1Sofosbuvir 1Sirolimus 1Saline Solution 1Ribavirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bronchiolitis Obliterans Syndrome × abexinostat × Clear all
NCT01149668 2013-06-19

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Pharmacyclics LLC.

Phase 1 Completed
7 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡